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What is already known about this topic?  118 
All existing severe asthma registries in the world were either country or region specific. Most 119 
importantly, none shared a common set of variables for data collection. This impedes data sharing and 120 
subsequently disallows data pooling to conduct research with robust sample size. 121 
What does this article add to our knowledge?  122 
This paper depicts a systematic method of soliciting group consensus on a topic that entails a spectrum 123 
of choices and viewpoints.  124 
How does this study impact our current management guidelines?  125 
Using the standardized minimal list of variables identified by our study, we hope to achieve data 126 
interoperability between severe asthma registries across the globe and subsequently improve patient 127 




Background: The lack of centralised data on severe asthma has resulted in a scarcity of information 130 
about the disease and its management. The development of a common data collection tool for the 131 
International Severe Asthma Registry (ISAR) will enable standardised data collection, subsequently 132 
enabling data interoperability. 133 
Objectives: To create a standardised list of variables for the first international registry for severe asthma 134 
via expert consensus. 135 
Methods: A modified Delphi process was used to reach consensus on a minimum set of variables to 136 
capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the 137 
field of severe asthma research. The process consisted of three iterative rounds. In each round, all Delphi 138 
panel members were issued an electronic ISAR Delphi workbook to complete and return to the ISAR 139 
Delphi administrator. Workbooks and result summaries were anonymously distributed by the Delphi 140 
administrator to all panel members at subsequent rounds. Finalisation of the core variable list was 141 
facilitated by two face-to-face meetings. 142 
Results: Of the initial 747 selected variables, the Delphi panel reached a consensus on 95. The chosen 143 
variables will allow severe asthma to be assessed against patient demographics and medical history, 144 
patient-reported outcomes, diagnostic information and clinical characteristics. Physician-reported 145 
outcomes such as non-adherence and information about treatment and management strategies will also 146 
be recorded. 147 
Conclusion: This is the first global attempt to generate an international severe asthma registry using a 148 
common set of core variables to ensure that data collected across all participating countries are 149 
standardised.  150 
 151 
Key words: Severe asthma, Disease registry, Delphi process 152 
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Abbreviation   
A&E Accident & Emergency 
ACQ Asthma Control Questionnaire 
ACT Asthma Control Test 
ADEPT Anonymised Data Ethics & Protocol Transparency 
Anti-IgE Anti-Immunoglobulin E Treatment 
Anti-IL-5 Anti-Interleukin-5 Treatment 
ATS American Thoracic Society 
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BSA Body Surface Area 
BTS British Thoracic Society 
CRF Case Report Form 
CT Computerised Tomography 
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EMA European Medicines Agency 
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GINA Global Initiative for Asthma 
ICS Inhaled Corticosteroids 
IgE Immunoglobulin E 
ISAR International Severe Asthma Registry 
ISC ISAR Steering Committee 
LABA Long-Acting Beta-Agonists 
LAMA Long-Acting Muscarinic Antagonist 
LTRA Leukotriene Receptor Antagonist 
OCS Oral Corticosteroids 
OPC Optimum Patient Care 
OPCRD Optimum Patient Care Research Database 
OPRI Observational and Pragmatic Research Institute Pte. Ltd. 
PC20 Concentration of Methacholine/Histamine needed to produce a 20% decrease in 
FEV1 
PEF Peak Expiratory Flow 
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Abbreviation   
R1 Delphi Round 1 
R2 Delphi Round 2 
R3 Delphi Round 3 
RAST Radioallergosorbent Test 
SABA Short-Acting Beta-Agonists 
SAWD Severe Asthma Web-based Database 
SPT Skin Prick Test 
 154 
 155 
Metrics information: 156 
Date: 17th April 2018 157 
Abstract word count: 250 words 158 
Text word count: 4252 words 159 
Number of references: 31 references 160 
Number of tables and figures: 3 tables and 2 figures 161 




Asthma affects 5−15% of the population worldwide and its prevalence has noticeably increased in 164 
recent decades (1). This heterogeneous disease, characterised by variable symptoms including cough, 165 
wheeze and dyspnoea, is associated with chronic airway inflammation. Management strategies, 166 
including asthma education, are aimed at achieving optimal disease control via minimisation of current 167 
symptoms and prevention of acute exacerbations using a stepwise approach to medication (2).  168 
Although most asthma patients have mild to moderate disease symptoms that may be well-controlled 169 
with standard treatment, a smaller sub-population remains uncontrolled and/or suffers from severe 170 
symptoms. The exact prevalence of severe asthma is uncertain but has been estimated at 5−10% of the 171 
asthma population (3-5). Such patients remain inadequately managed with the current standard of care 172 
(3), which includes high-dose inhaled corticosteroids with additional controllers and represent a 173 
significant unmet need. 174 
There is compelling evidence to suggest that better standardised care for severe asthma is needed, 175 
including the registration of systematic assessment and improved and aligned registries of patients 176 
whose symptoms fulfil the criteria for severe asthma (6). Indeed, registries are well established tools 177 
for tracking and reporting on the epidemiological attributes of a disease. They are valuable resources 178 
which enable treatment benefits and risks to be proactively monitored over time, through the collection 179 
of natural history data, and which aid the development of therapeutics and/or diagnostics. They can be 180 
used to gather information on disease progression and patient subgroups, facilitate patient recruitment 181 
into clinical trials, and generate real world evidence on the safety and cost effectiveness of new 182 
therapeutics (7). Notably, registries are increasingly required as part of the post-approval safety 183 
monitoring process of regulatory bodies for new treatments (7).  184 
The current registry landscape for severe asthma is viewed as a collection of divergent, national and 185 
regional registries. The design, development and maintenance of such registries has typically revolved 186 
around specific data collection platforms and drugs, leading to the creation of segregated systems with 187 
little or no collaboration between the different collections. Individual registries have limited power due 188 
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to the relative rarity of severe asthma and stringent inclusion criteria. Different objectives and 189 
governance rules also exist across different countries and/or organisations. These disparities can lead to 190 
country-specific registries collecting different data fields of various quality. These limitations lead to 191 
the implementation of only a subset of registry functions, resulting in the collection and analysis of 192 
limited data on severe asthma. Pooling data across multiple registries will improve the precision of 193 
incidence estimates, aid in identifying rare safety signals, and facilitate the exploration of possible drug-194 
demographic, drug-disease or drug-drug interactions in different sub-populations of the combined 195 
global severe asthma patients (8). To date, several national and regional severe asthma registries exist 196 
(9-12), but none has an agreed international focus and standard list of data fields.  197 
Using long-standing severe asthma registries from the United Kingdom (UK) (9) and Australia (11, 13), 198 
our aim was to gain expert consensus on a standardised list of variables on demographic, clinical 199 
characteristics, treatment and comorbidities to establish the first international registry for severe asthma 200 
so that data can be seamlessly exchanged between countries and institutions without system-specific 201 
differences.  202 




This study utilised a modified, 3-round Delphi method process (14) to select the common core variables 205 
to be collected in the International Severe Asthma Registry (ISAR). Variables were initially selected 206 
from previously existing national severe asthma registries. This helped to hasten the process of building 207 
the registry data collection framework by integrating real-world data elements that have been tested for 208 
feasibility of usage and collection.  209 
Panel selection 210 
To achieve consensus, it was essential for the Delphi panel to include appropriately qualified and 211 
experienced individuals who could provide critical and discrete input toward the issue. The ISAR 212 
Delphi panel consisted of 27 experts in the field of severe asthma research. The panel members were 213 
invited from 16 different countries (Supplementary Table 1), and were selected according to two or 214 
more of the following criteria:  215 
1. Evidence of relevant asthma research published in high-ranking peer reviewed journals (e.g. high 216 
number of citations and research items) 217 
2. A history of participation in the development and/or management of one or more severe asthma 218 
registries, epidemiological databases and scientific congress committees in a particular country 219 
and/or internationally 220 
3.  Experience as a medical provider with interest in advancing asthma management in clinical 221 
practice.  222 
All the 22 ISAR Steering Committee (ISC) members were included in the list of 27 Delphi panel 223 
members, and hence, the Delphi panel was highly representative of the ISC. The five Delphi panel 224 
members not on the ISC were: one pharmaco-epidemiologist, one health-economist, two severe asthma 225 
clinical researchers, and one severe asthma database manager. 226 
Modified Delphi process 227 
A modified Delphi process was used to reach consensus (15). The process consisted of three iterative 228 
rounds (R1, R2 and R3) (Figure 1) where each Delphi panel member was issued an electronic ISAR 229 
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Delphi workbook to review, provide suggestions and vote to select core variables. Members then return 230 
the completed Delphi workbooks anonymously, to the ISAR Delphi administrator within a two-week 231 
time frame stipulated for each round. The Delphi administrator directly corresponded with all panel 232 
members individually to ensure anonymity of replies and was responsible for disseminating a workbook 233 
and result summaries for each round.  234 
Delphi R1 235 
The Delphi workbook (The ISAR Delphi Workbook Round 1) was developed by consolidating the 236 
variable lists for the British (British Thoracic Society (BTS) Difficult Asthma Network) (9) and the 237 
Australian (Severe Asthma Web-based Database (SAWD)) (13) severe asthma registry. These variables 238 
were chosen as the initial bank of variables due to 15 years of usage and SAWD having the most number 239 
of variables amongst the existing severe asthma registries as of 2017. However, as there were 907 240 
variables in both registries combined, and given that there are limited resources available for data 241 
collection, this exercise set out to determine not only the most appropriate variables but also to ensure 242 
that data collection for such variables can be sustained in a clinical setting. 243 
Information from both registries was formally requested and extracted to develop two sets of variables: 244 
there were 115 variables in the “potential core” list (variables common to both registries; please see 245 
Table 1 for a sample) and 632 variables in the “suggest” list (variables unique to either registry; please 246 
see Table 2 for a sample). 247 
The workbook was developed using Microsoft Excel 2016 MSO (V16.0) and consisted of a two-tab 248 
spreadsheet with response-controlled questionnaires. On tab one, displaying the potential core list 249 
(Table 1), panel members were required to select an option (“Yes” or “No”) via a drop-down menu for 250 
each variable, indicating whether they concur that the variable would be part of the ISAR core variable 251 
list. Panel members were also encouraged to nominate variables from the suggest variable list (Table 252 
2) on tab two and/or propose new variables. Experts were also encouraged to provide comments for 253 
excluding or including variables. 254 
The Delphi workbook was sent to each Delphi panel member electronically, to be completed 255 
independently and returned via email to the Delphi administrator. At round closure, the Delphi 256 
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administrator anonymised all returned workbooks and compiled all replies to tabulate frequency of 257 
responses, “Yes” and “No”, for each variable on the lists.  258 
Variable consensus was then evaluated using summary statistics (frequency counts) generated with a 259 
statistical program (Stata 14, StataCorp LLC, Texas, USA). Each “potential core” variable that received 260 
a majority (66.6%) or more consensus from the Delphi panel was selected as an ISAR core variable. 261 
However, with the first-round of results, to exercise rigorous oversight, only variables with 100% 262 
consensus were added to the core list. Variables with less than 50% consensus were reviewed and 263 
removed. All other potential core variables were circulated for another round of review (Delphi R2). In 264 
tandem to the potential core, the suggest list of variables was also reviewed to evaluate the number of 265 
votes by the Delphi panel. Variables with at least two “Yes” votes were then circulated for another 266 
round of review (Delphi R2). The Delphi R1 results were presented to the ISC (much of the Delphi 267 
panel consisted of ISC members (22/27)) during the inaugural ISAR Steering Committee meeting in 268 
March 2017.  269 
Delphi R2 270 
As in R1, the expert panel was requested to engage in a similar voting process for the Delphi R2 via a 271 
limited-response electronic questionnaire (The ISAR Delphi Workbook Round 2). The Delphi R1 272 
summary results and panel member comments (“Reasons”) were anonymised and provided in the R2 273 
workbook to facilitate an informed decision. Moreover, “Additional Information” on the use or 274 
functionality of these variables in the ISAR registry was provided to aid panel members in their 275 
decision. Potential core variables with less than 100% and greater than 50% consensus from R1 were 276 
included in the R2 workbook. Additionally, suggest variables with at least two or more votes by Delphi 277 
panel members were disseminated for a full panel poll in R2. 278 
Delphi R3 279 
The Delphi panel also took part in R3 via a limited-response electronic questionnaire (The ISAR Delphi 280 
Workbook Round 3). Suggest variables and potential core variables were vetted concurrently in the 281 
same manner in R3, following finalisation of suggest variables during R3 discussions by the Delphi 282 
panel. Suggest variables from R2 which had attained more than 50% consensus and potential core 283 
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variables from R2 on which a consensus was not reached (>50% and <66.6% consensus) were circulated 284 
for another round (R3). In addition, due to high relatability, nine of the suggest variables from R2 were 285 
consolidated into four variables/questions after discussion at the inaugural Steering Committee meeting. 286 
These were: current occupation, age at start of asthma symptoms, environmental allergen test 287 
conducted, and current clinical management plan. These variables were added to the R3 workbook to 288 
ensure full vetting and review by the panel. 289 
The ISAR core variables were finalised during the second ISAR Research Prioritisation meeting in May 290 
2017. R3 results and all outstanding concerns raised by panel members, such as data field options for 291 
variables including ethnicity and occupation, were discussed and resolved at the second Steering 292 
Committee face-to-face meeting. The participants were requested to re-evaluate the remaining five 293 
undecided variables to arrive at a consensus on which variables would be submitted for another Delphi 294 
round and hence, which would be retained or removed from the final ISAR core variable list. The 295 
discussion was mediated by the Delphi neutral facilitator, who closed the gap of consensus by reminding 296 
the Steering Committee and/or Delphi members of the aim of the ISAR registry and the international 297 
study population under consideration. The final core variable list was shared with the Delphi panel in a 298 
Case Report Form (CRF). All chosen core variables were represented in the final CRF questionnaire 299 
format. 300 
All variables that were not selected for the core list at the end of the Delphi process were compiled 301 
into a separate list. This list later gave rise to standard bolt-on variables, named “research variables”. 302 
Research variables are available to be adopted by a participating country-specific registry according to 303 
local research interests and capacity to collect and store data. A participating country is encouraged to 304 
add variables outside the core list to the country-specific registry, including and/or beyond the 305 




Data Sharing 308 
For the three types of variable lists shown below, the corresponding variable name and the related 309 
meta-data, such as format and response options, are demonstrated in the “ISAR Delphi Process 310 
Variables Workbook”:  311 
1. Sheet 1: Matched "Potential Core" Variables 312 
(List of Matching variables from the BTS and SAWD registries) 313 
2. Sheet 2: Unmatched "Suggest" Variables 314 
(List of Non-matching variables from the BTS and SAWD registries) 315 
3. Sheet 3: Variables disqualified  316 
(List of variables removed from the total number of matching and non-matching variables) 317 
This data has been deposited into a secure electronic repository via Mendeley Data 318 
(http://dx.doi.org/10.17632/xdrdy37tbm.3). 319 




Delphi R1 322 
Fifteen of the 27 members of the panel participated in Delphi R1 (55.6%); 28 of 115 initial potential 323 
core variables achieved complete consensus with 100% agreement for inclusion into the ISAR core 324 
variable list. Eighty of the remaining variables received greater than 66.6% and less than 100% 325 
consensus, six were undecided (50−66.6%) and one variable did not achieve consensus (<50%) 326 
(Supplementary Table 2). A total of 86 potential core variables (less than complete consensus (80) and 327 
undecided (6) variables)) were fed into the second round of the Delphi process. 328 
Additionally, 54 suggest variables had attained at least two or more votes by the Delphi panel and 329 
moved on to the second round of the Delphi process (R2) (Supplementary Table 2). The remaining 578 330 
suggest variables were then appropriately reviewed and removed from the Delphi process.  331 
Potential core variables with undecided consensus were: the GINA (Global Initiative for Asthma) 332 
asthma control questionnaire and patient status as a research subject. The asthma medication question 333 
regarding anti-leukotriene level received less than 50% consensus and was removed from the ISAR 334 
potential core variable list and the Delphi review process after assessment by the Delphi neutral 335 
facilitator. 336 
Delphi R2 337 
Thirteen panel members participated in R2 (48%). Eighty-six (less than complete consensus (80) and 338 
undecided (6) variables) potential core variables were considered in R2. Of them, 74 achieved 339 
consensus with more than 66.6% agreement for inclusion into the ISAR core variable list. Of the 340 
remaining variables, eight were undecided and four did not achieve consensus. In addition, nine of 54 341 
variables in the suggest variable list attained more than 66.6% agreement for inclusion into the ISAR 342 
core variable list (Supplementary Table 3). 343 
Of the eight undecided variables, comorbidities (Ischaemic Heart Disease and Heart Failure), asthma 344 
medication (Inhaled corticosteroid [ICS], Long-acting beta-agonist [LABA], long-acting muscarinic 345 
antagonist [LAMA]) and allergen testing details were included in Delphi R3. As suggested by Delphi 346 
panel members, the probing order for the variable “Was blood eosinophil count collected during an 347 
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exacerbation event?” was changed to a branch question versus a stand-alone question and added to the 348 
core variable list after a thorough review by the neutral facilitator.  349 
Variables without consensus were: patient involvement in research trials, use of a nebuliser, SABA 350 
(short acting beta-agonists) and experience of adverse events. After further review by the Delphi neutral 351 
facilitator, these variables were removed from the core variable list.  352 
Results from R2 were presented and discussed at the inaugural Steering Committee meeting in March 353 
2017. The GINA Asthma Control questionnaire was chosen as the patient-reported measure of asthma 354 
control, and therefore included in the core variable list. Due to highly related variables, the nine newly 355 
suggest variables were consolidated into four variables after detailed discussion and review among the 356 
Delphi panel. Altogether, eight undecided potential core variables and the four consolidated suggest 357 
variables were included into R3 of the Delphi process. 358 
Delphi R3 359 
Fourteen Delphi members participated in R3 (51.9%). Four of 12 R3 potential core variables achieved 360 
consensus with more than 66.6% agreement for inclusion into the ISAR core variable list 361 
(Supplementary Table 4). Of the remaining eight variables, five were undecided, and three did not 362 
achieve consensus. Upon review by the Delphi neutral facilitator, and a face-to-face discussion with the 363 
Steering Committee in May 2017, one undecided variable was included into the core variable list. All 364 
three non-consensus variables and remaining four undecided variables were removed from the core list. 365 
R3 resulted in five variables added to the core variable list. With all “potential core” variables achieving 366 
a status of consensus or non-consensus, the Delphi exercise ended at R3. 367 
To further streamline the process, undecided variables and non-consensus variables such as asthma 368 
medication devices, prior clinical management plan, adverse events and comorbidities (Ischaemic Heart 369 
Disease and Heart Failure) were removed from the core variable list. Date of bone densitometry was 370 
added to the core list after ISC discussion, despite the undecided status. 371 
During the conclusion of R3 at the second ISAR Steering Committee meeting in May 2017, a majority 372 
of the Delphi panel, all steering committee members (22 of 27) and the Delphi neutral facilitator agreed 373 
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that ISAR should include two broad categories of patients similar to the European Respiratory Society 374 
(ERS)/American Thoracic Society (ATS) Task Force’s definition of Severe Asthma: patients receiving 375 
GINA Step 5 treatment, and patients with uncontrolled asthma at some point while receiving GINA 376 
Step 4 treatments (3). Patients were considered to have uncontrolled asthma were defined as those 377 
having severe asthma symptoms, consisting of poor symptom control, airflow limitation, or serious 378 
exacerbations as per the ERS/ATS guidelines, or suffering exacerbations requiring two or more courses 379 
of oral corticosteroids.  380 
The overall results from the Delphi process are summarised in Figure 2. 381 
Final ISAR core variable list 382 
The core variables that achieved consensus via the closely guided three rounds of Delphi were included 383 
in the final core variable list (Table 3). The final ISAR core variable list consists of 95 variables, 83 384 
variables that require data entry and 12 variables that do not require data entry (auto-populated). These 385 
variables are classified into 13 variable categories. 386 
The core variables were reported in a CRF, which allowed a probing mechanism to take place with a 387 
branched questionnaire. A CRF was constructed to facilitate the process of data collection with 388 
enhanced clarity. 389 




The aim of this Delphi-based study was to reach consensus among specialists in the field of severe 392 
asthma on a core set of data fields to include in the International Severe Asthma Registry. Using the 393 
knowledge and experience of an international panel of severe asthma experts, workable criteria for 394 
registry purposes, a core set of variables and a potential method to unify data for severe asthma from 395 
across the globe were generated. Analyses of these registry data will facilitate insight into this 396 
heterogeneous disease on a global scale. All potential variables underwent a rigorous, stepwise 397 
consensus process to ensure the collection of the minimum required information to effectively study 398 
the development, therapeutics and management of patients with severe asthma. 399 
Definitions, such as severe asthma, were based on expert opinion and precedence of use, because 400 
achieving consensus of what constituted severe asthma at an early stage in the process was important. 401 
The inclusion criteria, patients on GINA Step 5 therapy or uncontrolled on Step 4 therapy, were agreed 402 
upon by a majority of the panel to ensure the inclusion of severe asthma patients in a real-world setting. 403 
These criteria served the primary purpose of the registry to prospectively survey severe asthma patients. 404 
In addition, the inclusion criteria allowed the core data to be used for broader purposes (e.g. uncontrolled 405 
asthma etc.). The ISAR is not intended to assess the validity of real-life clinical practice, but merely to 406 
observe the evolving patterns of clinical care to ultimately evaluate its safety and/or effectiveness in 407 
order to improve the lives of patients. As such, no confirmation of asthma is required for enrolled 408 
subjects. 409 
Of the initially circulated potential core and suggest variables, 95 variables achieved Delphi panel 410 
consensus. These variables represented 13 categories pertaining to the assessment and treatment of 411 
patients with severe asthma. Each category will serve to collect subsets of information essential for a 412 
more complete understanding of the disease. The successful limitation of core variables to less than 100 413 
has resulted in an applicable CRF with a relatively small data entry burden for healthcare professionals 414 
who are participating in the registry. The specific domains that will enhance global registry recruitment 415 
and utility are discussed below. 416 
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Patient details and medical history 417 
Patient demographic and medical history data fields will allow patients to be categorised (16). The 418 
panel-approved variables were chosen to ensure a comprehensive set of patient characteristics are 419 
collected for patient aggregation. Previous studies have shown that many patients overestimate their 420 
level of asthma control and underestimate the severity of their condition, indicating that they tolerate 421 
symptoms and lifestyle limitations (17-19). The GINA questionnaire was the preferred tool for this 422 
assessment, because previous studies have shown that it does not overestimate the proportion of patients 423 
with controlled asthma and is therefore more likely to give a less exaggerated score compared to other 424 
available questionnaires (20).  425 
Diagnostics 426 
The expert panel agreed to collect screening and diagnostic results to help identify the care requirements 427 
of individual patients. Biomarkers such as peripheral blood and sputum eosinophils, and fractional 428 
exhaled nitric oxide (FENO) have been shown to be useful for the management of asthma (21, 22), and 429 
may help identify specific subtypes of severe asthma likely to benefit from treatment with novel 430 
biological agents.  431 
Adherence and comorbidities 432 
Non-adherence to therapy is approximately 50% in adults with severe asthma (23-25). Physicians need 433 
to ensure that patients are satisfied with their medication to increase adherence and optimise disease 434 
control (26). The potential for ISAR to investigate non-adherence across different geographical regions, 435 
with likely different healthcare systems, availability of medications and access to specialists and asthma 436 
education, was noted.  437 
A real-life study on asthma control reported that physicians believed that the main reasons for lack of 438 
asthma control included comorbidities, as seen in 36.2% of patients, continued exposure to 439 
irritants/triggers in 34.0% of patients, and inadequate adherence to treatment in 27.0% of patients (27).  440 
Treatment management plan 441 
Asthma patient management practices among adults have been found to be inadequate in many practices 442 
in Europe (28). Along with the information that ISAR will collect on clinical outcomes and 443 
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demographic characteristics, the best treatment management plan by patient group will be assessed. 444 
Moreover, the panel agreed to collect broad treatment options to ensure that all participating countries 445 
will be able to contribute without subjection to individual country specifications. 446 
Strengths and weaknesses 447 
The Delphi panel was composed of international severe asthma professionals to ensure that 448 
recommendations recognised and reflected all social nuances specific to the participating countries 449 
while maintaining applicability in more than one healthcare setting and location. Eighteen unique 450 
Delphi panel members from 16 different countries participated in one or more Delphi rounds. This 451 
allowed broad consensus to be obtained. Using a group approach ensured that more comprehensive 452 
expertise was extrapolated than from any individual member alone. The selected panel of experts were 453 
chosen not only for their expertise in the research field, but also for their relevant medical practice and 454 
experience with developing and/or managing databases or regional/national severe asthma registries. 455 
The Delphi method ensured versatility of application and enhanced the sustainability of ISAR in the 456 
field due to panel members’ involvement and cooperation in the generation of the registry data 457 
specification.  458 
The anonymity of the survey helped to reduce the influence of dominant individuals which may become 459 
apparent during face-to-face meetings. However, the anonymity may also have reduced the positive 460 
effects of interaction during face-to-face meetings, depriving experts of important exchanges of 461 
information which would help to identify and discuss reasons for disagreement (29). The modified 462 
Delphi process maximised the benefits of both consensus methods through the initial collection of 463 
information via questionnaires followed by structured in-person meetings. ISAR meetings were 464 
organised to allow panel and/or steering committee members to discuss variables and selection criteria 465 
and resolve remaining disagreements face to face.  466 
The Delphi process was predominantly carried out online and was therefore efficient and economically 467 
viable in terms of investigator time and funding. Furthermore, it facilitated rapid communication 468 
between a global panel of experts. However, the response rate was not 100%, with a total of 18 out of 469 
27 experts (62%) responding to the three Delphi rounds. Although early experiments using Delphi 470 
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suggested that group error was reduced with increased group size (30), more recent studies have found 471 
that reliable outcomes can be obtained with a relatively small number of Delphi experts (31). The 472 
number of specialised experts in a specific field may be limited. The consistency of expert training may 473 
allow small numbers of experts to reliably participate in the generation of valid stable responses. The 474 
selection of the panel is therefore extremely important. However, due to the consistency in the number 475 
of experts who participated in each round (R1=15, R2=13, R3=14), the possibility of reaching a 476 
consensus was conserved. 477 
The Delphi panel was not fully representative of the diversity amongst stakeholders of respiratory 478 
health, such as healthcare payers or patients. The wide range of opinions gathered could be bolstered 479 
with an increase in the variety of stakeholders. 480 
The design of the Delphi process, which involved the gathering of opinions from a group of experts, 481 
dilutes the opinion of a single expert. Thus, bias is decreased and diversity within the expert panel is 482 
maximised, which in turn decreases the possibility of overlooking the obvious facets of the questions. 483 
Despite the incomplete response rate and possible changes in experts participating in each round, the 484 
final results covered a wide range of areas where consensus was achieved. It is important to remember 485 
that the Delphi method is a tool to be used in conjunction with other processes which can be used to 486 
answer a wide range of research questions. 487 
It is beyond the scope of this study to investigate the reasons behind the convergent or divergent views 488 
of the panel. However, these reasons should be explored next to further validate the methodology of a 489 
Delphi exercise. 490 
Conclusion 491 
Using the Delphi process to gain an international consensus among severe asthma experts across sixteen 492 
countries, a standardised framework was developed to describe patients with severe asthma, which may 493 
help to define a link between best practices and improved outcomes. These questions cover a 494 
comprehensive range of variables from patient demographics, diagnostics, patient- or physician-495 
reported outcomes and treatment management plans. Collecting a minimum necessary amount of real-496 
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life data on a severe asthma patient will not only enhance the quality of patient care, but also ensure the 497 
sustainability of ISAR as an international registry given that there are often limited resources available 498 
for data collection. This is the first attempt to develop such a registry on a global scale within the setting 499 
of severe asthma. The main goal of this effort is to standardise data collection to enable pooling of 500 
multiple data sources and assist in clinical decision-making for healthcare professionals around the 501 
world. The next step is to enrol patients and collect data that will allow gaps in diagnosis and treatment 502 
to be identified, and solutions to be found, which will help bridge these gaps and thus bring us one step 503 
closer to controlling severe asthma. 504 
Acknowledgements 505 
The International Severe Asthma Registry is conducted by Optimum Patient Care Global Limited, and 506 
co-funded by Optimum Patient Care Global and AstraZeneca. 507 
  508 
24 
 
References  509 
1. Martinez FD, Vercelli D. Asthma. Lancet. 2013;382(9901):1360-72. 510 
2. (GINA) GIoA. Global strategy for asthma management and prevention 2017 [cited 2017 21 511 
June]. Available from: http://ginasthma.org/2017-gina-report-global-strategy-for-asthma-512 
management-and-prevention/. 513 
3. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS 514 
guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343-73. 515 
4. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005;172(2):149-60. 516 
5. von Bulow A, Kriegbaum M, Backer V, Porsbjerg C. The prevalence of severe asthma and 517 
low asthma control among Danish adults. J Allergy Clin Immunol Pract. 2014;2(6):759-67. 518 
6. Bel EH, Sousa A, Fleming L, Bush A, Chung KF, Versnel J, et al. Diagnosis and definition of 519 
severe refractory asthma: an international consensus statement from the Innovative Medicine 520 
Initiative (IMI). Thorax. 2011;66(10):910-7. 521 
7. Gliklich RE DN, Leavy MB. In: (US) AfHRaQ, editor. Registries for Evaluating Patient 522 
Outcomes: A User's Guide. 3rd ed. Rockville (MD)2014. 523 
8. Maio S, Baldacci S, Bresciani M, Simoni M, Latorre M, Murgia N, et al. RItA: The Italian 524 
severe/uncontrolled asthma registry. Allergy. 2017. 525 
9. Heaney LG, Brightling CE, Menzies-Gow A, Stevenson M, Niven RM, British Thoracic 526 
Society Difficult Asthma N. Refractory asthma in the UK: cross-sectional findings from a UK 527 
multicentre registry. Thorax. 2010;65(9):787-94. 528 
10. Maio S, Baldacci S, Cerrai S, Sarno G, Bresciani M, Latorre M, et al. The Italian registry for 529 
severe/uncontrolled asthma. European Respiratory Journal. 2016;48(suppl 60). 530 
11. PROTOCOL – SAWD & Research Register Version 4.0. 2015. [cited 2018 09 April]. 531 
Available from: http://www.severeasthma.org.au/wp-content/uploads/2017/09/PROTOCOL-SAWD-532 
Research-Register-Version-4.0-1st-December-2015.pdf. 533 
12. Senna G, Guerriero M, Paggiaro PL, Blasi F, Caminati M, Heffler E, et al. SANI-Severe 534 
Asthma Network in Italy: a way forward to monitor severe asthma. Clin Mol Allergy. 2017;15:9. 535 
13. Harvey E, Gibson P, Bardin P, Peters M, Reynolds P, Upham J, Reddel H, Kritikos V, 536 
Katelaris C, Cochrane B, Thien F, Azad A, Hew M, Yang I, Brockway B, Garrett J, Yap E, Jones S, 537 
Southcott A, Jayaram L, E.g. Gillman A, Uddin N, Rimmer J, Katsoulotos G, Smith V, Jenkins C, 538 
Wark P, McDonald V. Asthma and Allergy SIG 2 Poster Presentations; Characterisation of severe 539 
asthma phenotypes via a severe asthma registry: The severe asthma Web-based database. 540 
Respirology. 2016;21(Issue S2):108-15. 541 
14. Pill J. The Delphi method: Substance, context, a critique and an annotated bibilography. 542 
Socio-Economic Planning Science. 1971;5:55-71. 543 
15. Eubank BH, Mohtadi NG, Lafave MR, Wiley JP, Bois AJ, Boorman RS, et al. Using the 544 
modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients 545 
with rotator cuff pathology. BMC Med Res Methodol. 2016;16:56. 546 
16. Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J. 547 
2004;24(5):822-33. 548 
17. Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma 549 
patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. 550 
18. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European 551 
patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim 552 
Care Respir Med. 2014;24:14009. 553 
19. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity 554 
and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy 555 
Clin Immunol. 2004;114(1):40-7. 556 
20. Vermeulen F, de Meulder I, Paesmans M, Muylle I, Bruyneel M, Ninane V. Asthma control 557 
measurement using five different questionnaires: a prospective study. Respir Med. 2013;107(9):1314-558 
21. 559 
21. Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G, et al. Exhaled 560 
nitric oxide: a predictor of steroid response. Am J Respir Crit Care Med. 2005;172(4):453-9. 561 
25 
 
22. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for 562 
severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 563 
2012;380(9842):651-9. 564 
23. Boulet LP, Vervloet D, Magar Y, Foster JM. Adherence: the goal to control asthma. Clin 565 
Chest Med. 2012;33(3):405-17. 566 
24. De Smet BD, Erickson SR, Kirking DM. Self-reported adherence in patients with asthma. 567 
Ann Pharmacother. 2006;40(3):414-20. 568 
25. Gamble J, Stevenson M, McClean E, Heaney LG. The prevalence of nonadherence in difficult 569 
asthma. Am J Respir Crit Care Med. 2009;180(9):817-22. 570 
26. van Boven JF, Ryan D, Eakin MN, Canonica GW, Barot A, Foster JM, et al. Enhancing 571 
Respiratory Medication Adherence: The Role of Health Care Professionals and Cost-Effectiveness 572 
Considerations. J Allergy Clin Immunol Pract. 2016;4(5):835-46. 573 
27. Allegra L, Cremonesi G, Girbino G, Ingrassia E, Marsico S, Nicolini G, et al. Real-life 574 
prospective study on asthma control in Italy: cross-sectional phase results. Respir Med. 575 
2012;106(2):205-14. 576 
28. Vermeire PA, Rabe KF, Soriano JB, Maier WC. Asthma control and differences in 577 
management practices across seven European countries. Respir Med. 2002;96(3):142-9. 578 
29. Keeney S, Hasson F, McKenna HP. A critical review of the Delphi technique as a research 579 
methodology for nursing. Int J Nurs Stud. 2001;38(2):195-200. 580 
30. Adler M, Ziglio E. Gazing into the oracle: The Delphi method and its application to social 581 
policy and public health: Jessica Kingsley Publishers; 1996. 582 
31. Akins RB, Tolson H, Cole BR. Stability of response characteristics of a Delphi panel: 583 
application of bootstrap data expansion. BMC Med Res Methodol. 2005;5:37.  584 
32. Vrijens B, Dima AL, Van Ganse E, van Boven JF, Eakin MN, Foster JM, et al. What We 585 
Mean When We Talk About Adherence in Respiratory Medicine. The journal of allergy and clinical 586 
immunology In practice. 2016;4(5):802-12. 587 
 588 
 589 
  590 
26 
 
Table 1: Sample of the “Potential Core” variable list from the International Severe Asthma Registry Delphi 591 




















Date of visit Date  DDMMYY   
Date of birth Date  DDMMYY   







East Asian/ African/ 
Mixed/ Other 
   
Height Decimal   M   




button     
 593 
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Table 2: Sample of the “Suggest” variable list from the International Severe Asthma Registry Delphi 595 
workbook Round 1 596 















Neutrophils Decimal  %   
Eosinophils Decimal  %   
Date of sputum Date  DDMMYY   
Sputum processing 
protocol Text     
Bronchial epithelial cells Decimal  %   
Bronchial epithelial cells Decimal  109/L   
Macrophages Decimal   %   
Lymphocytes Decimal  %   
Samples stored locally for 
biobanking 
Radio 
button No/Yes    
  597 
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Table 3: Final core variable list 598 
Category Variable Field Name 
Inclusion Criteria 
1) Receiving GINA Step 5 therapy 
2) Uncontrolled receiving GINA Step 4 (ERS/ATS Guidelines) therapy: 
a. Having severe asthma symptoms including poor symptom control, airflow 
limitation, and serious exacerbations 
b. Frequent severe asthma exacerbations requiring systemic corticosteroids. 
Patient fulfils the inclusion criteria for ISAR 
Patient Details 
Date of visit  
Date of birth 
Age at assessment  
Gender 
Ethnicity 
Body Surface Area 




Occupation Current occupation of the patient 
Medical History 
Current smoking status of patient 
Pack years 
• Number of cigarettes smoked per day 
• Number of smoking years 
Years since smoked 
 
Age at which asthma symptom began 
Number of exacerbations requiring rescue steroids in the past 12 months 
Number of episodes of invasive ventilation ever 
Number of A&E attendances for asthma in the past 12 months 






Atopic Disease (Atopic Dermatitis and allergic rhinitis). 
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Table 3: Cont. 600 
Category Variable Field Name 
Blood/Sputum 
Highest blood eosinophil count within the past year 
Date of highest blood eosinophil count within the past year 
Was this highest blood eosinophil count during an exacerbation event 
Highest blood eosinophil count within the past year and not during exacerbation 
Date of highest blood eosinophil count within the past year and not during exacerbation 
 
Current blood eosinophil count 
Date of current blood eosinophil count 
 
Highest sputum eosinophil count within the past year 
Date of highest sputum eosinophil count within the past year 
 
IgE count 
Date of IgE count 
Diagnostics 
Chest CT scan 
Date of chest CT scan 
Bone densitometry (DEXA) 







Pre-bronchodilator FEV1 (% predicted) 
Post-bronchodilator FEV1 (% predicted) 
Predicted FVC 
Pre-bronchodilator FVC (% predicted) 
Post-bronchodilator FVC (% predicted) 
FEV1/FVC ratio pre-bronchodilator (%) 
FEV1/FVC ratio post-bronchodilator (%) 
 
PC20 methacholine/histamine test 
Date of PC20 test 
PC20 test result 
 
Fractional Exhaled Nitric Oxide (FENO) test 
Date of FENO test 
FENO test result 
  601 
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Table 3: Cont. 602 
Category Variable Field Name 
Allergen Testing 
Environmental Allergen Test  
 
Serum allergy test: Positive to allergen  
Serum allergy test: Specify positive allergen and result 
Serum allergy test: Date 
 
Skin prick test: Positive to allergen  
Skin prick test: Specify positive allergen and result  
Skin prick test: Date 
Asthma Control 
GINA Asthma Control Questionnaire 
In the past 4 weeks, did the patient have: 
Daytime symptoms more than twice per week 
Any activity limitation 
Any nocturnal symptoms/awakening 
Reliever medication use more than twice per week 




Maintenance Oral Corticosteroids 
Start Date of Oral Corticosteroids 
ICS+LABA combination therapy 
Start Date of ICS+LABA combination therapy 
ICS (only) 
Start Date of ICS (only) therapy 
LABA (only) 
Start Date of LABA (only) therapy 
LAMA 
Start Date of LAMA therapy 
Theophyllines 
Start Date of Theophyllines therapy 
Leukotriene Receptor Antagonist (LTRA) 
Start Date of LTRA therapy 
Anti-IgE Treatment 
Start Date of Anti-IgE therapy 
Anti-IL-5 Treatment 
Start Date of Anti-IL5 therapy 
Macrolide Antibiotic Treatment 
Start Date of Macrolide Antibiotic therapy 
Other steroid sparing agents 
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Table 3: Cont. 604 
Category Variable Field Name 
Adherence 
 





Other factors contributing to severe asthma symptoms2 
Current Clinical Management Plan3 
 
                                                          
1 “Evidence of poor adherence”:  
This variable has the response options: “No”, “Yes: Subjective measure” and “Yes: Objective measure” 
Poor Adherence to Treatment can be indicated by selecting either (a) or (b): 
(a) Subjective measure (e.g. Clinical Impression, self-ending): Opinion of a medical personnel for poor 
adherence to asthma medication therapy or patient self-report 
• For example32.  
i. Impression of “Non-persistence”: Patient stops taking medication. 
ii. Impression of “Non-implementation”: Patient does not take medication as 
prescribed. 
(b) Objective measure (e.g. Prescription Records, electronic monitoring): Evidenced by medical records 
detailing asthma medication prescriptions being issued and inadequately filled or electronic 
monitoring obtained by smart inhalers patterns.  
• For example: 
i. Medication Possession Ratio (MPR)= (Sum of days’ supply for all fills/Number of 
days) X 100% <80% threshold 
2 “Other factors contributing to severe asthma symptoms”:  
This variable calls for a trained clinician’s perception or opinion on any other external factors (if any) that could 
contribute to the severe asthma symptoms of the patient. 
• For example: 
o Weather (cold air) 
o Air pollution 
o Physical Activity (Exercise-induced asthma symptoms) 
o Occupational triggers (workplace irritants, gases, chemical fumes,dust) 
o Strong smells (Perfumes) 
o Prior Respiratory Infections 
3 “Current Clinical Management Plan”: 
This variable aims to record the asthma action plan for a patient to review efficacy over time. 
• For example: 
o Entry into Clinical Trial 
 If the patient is deemed suitable to benefit from a clinical trial drug 
o Discharge to local asthma service 
 If the patient has shown alleviated asthma symptoms 
o Optimisation of current asthma therapy 
 If the patient’s current asthma therapy is titrated for better asthma 
management 
o Bronchial Thermoplasty 
 If the patient is eligible to have a bronchial thermoplasty surgery to 
manage their asthma 
o Biologic Therapy 
 If the patient is prescribed biologic therapy 
o Others: 
 Asthma education 





Figure Legend 606 
Figure 1: General flow of the International Severe Asthma Registry (ISAR) Delphi process showing topics 607 
discussed in each round 608 




BTS, British Thoracic Society; SAWD, Severe Asthma Web-based Database 
Delphi R1
-Consolidated list of 
BTS and SAWD 
registry variables
Delphi R2
-Variables with less 
than 100% and more 
than 50% consensus
- Suggested variables 







































BTS, British Thoracic Society; ISC, ISAR Steering Committee; SAWD, Severe Asthma Web-based Database 
100% complete consensus: 28 
Less than complete consensus: 80 
Undecided: 6 









Without consensus: 3 
Delphi R1: 632 suggested variables 
Selected variables: 54 
 
Delphi R3 results discussed and presented at the second ISC meeting 
• Undecided variables added to core: 1 
• Inapplicable variables removed from potential core (106) variables: 12 
 
Total ISAR core variables: 95 
Potential core variable list: 115 
Combined BTS and SAWD registry 
 
9 selected variables 
were consolidated 
into 4 at the inaugural 
ISC meeting 
 
Delphi R2: 54 suggested variables 
Selected variables: 9 
 
Suggested variable 
 list: 632 






Supplementary Table 1: International Severe Asthma Registry Delphi panel members 
Delphi Panel Member Country 
David Price (independent facilitator) Singapore 
Liam Heaney United Kingdom 
Andrew Menzies-Gow United Kingdom 
Giorgio Walter Canonica Italy 
Eric Van Ganse France 
Manon Belhassen France 
Roland Buhl Germany 
Anke-Hilse Maitland- van der Zee The Netherlands 
Leif Bjermer Sweden 
Peter Gibson Australia 
Vibeke Backer Denmark 
Chin Kook Rhee South Korea 
Nikos Papadopoulos Greece 
Rohit Katial USA 
Lauri Lehtimäki Finland 
J.Mark FitzGerald Canada 
Guy Brusselle Belgium 
Luis Perez de Llano Spain 
Francisco de Borja Garcia-Cosio Piqueras Spain 
Loo Chian Min Singapore 
Sven Erik Dahlen Sweden 
Mark Hew Australia 
Matthew Peters Australia 
Erin Harvey Australia 
Katia M C Verhamme The Netherlands 
Job FM van Boven The Netherlands 





Supplementary Table 2: Delphi R1 results summary 
R1 variable summary Number Criteria Remarks 
Potential Core Variables 
Total number of variables 115   
Undecided 6  50 to 66.6% Entered in R2 
Without consensus 1  <50% Removed from core  
Less than complete 
consensus 80 >66.6% and <100% Entered in R2 
Complete consensus 28  100% Included in core 
Suggested Variables 
Total number of variables 632   





Supplementary Table 3: Delphi R2 results summary 
R2 variable summary Number Criteria Remarks 
Potential Core Variables 
Total number of variables 86   
Undecided 8  50 to 66.6% Entered in R3 
Without consensus 4  <50% Removed from core 
Consensus 74  >66.6% Included in core 
Suggested Variables 
Total number of variables 54   
Highly suggested 9 ≥2 suggestions Consolidated to 4 at the inaugural 





Supplementary Table 4: Delphi R3 results summary 
R3 variable summary Number Criteria Remarks 
Total number of variables 12   
Consensus 4 >66.6% Included in core 
Undecided 5 50 to 66.6% 1 included in core  4 removed from core 
Without consensus 3 <50% Removed from core 
 
 
